TJ Biopharma Co., Ltd.

Privately held: no public share price

Assets

(3 total)
3Total Assets
0Approved
1Phase 3 / Filed
2Phase 1–2 / Early
4Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Efmedaglutide alfa(Shanmeining)
Phase 3
GLP-1 receptorProtein / enzyme therapeutic
ObesityType 2 Diabetes
Phase 2/3
CD73Monoclonal antibody
Non-Small Cell Lung Cancer
Phase 2
IL-6 transProtein / enzyme therapeutic
Inflammatory Bowel Disease
Ulcerative Colitis

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
August 2028 (1)
UliledlimabPhase 2/3Non Small Cell Lung Cancer
Est. primary completion 2028-08-05 · NCT06984588 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

30 September 2026Topline resultTG103TG103 plus metformin Phase 3 vs dulaglutide (NCT06235086) met its primary endpoint
CSPC Pharmaceutical Group Limited · Source ↗
June 2026Filing acceptedTG103NMPA accepts the second marketing application for efmedaglutide alfa (TG103, Shanmeining) in type 2 diabetes
China, NMPA · CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. · Source ↗
October 2025Filing acceptedTG103NMPA accepts the BLA for efmedaglutide alfa (TG103) in overweight or obesity
China, NMPA · CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. · Source ↗

Financial reports

No financial reports recorded.